KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Depreciation and Depletion (2016 - 2025)

Biomarin Pharmaceutical's Depreciation and Depletion history spans 16 years, with the latest figure at $13.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation and Depletion rose 13.79% year-over-year to $13.2 million, compared with a TTM value of $48.5 million through Dec 2025, up 4.08%, and an annual FY2025 reading of $48.5 million, up 4.08% over the prior year.
  • Depreciation and Depletion for Q4 2025 was $13.2 million at Biomarin Pharmaceutical, up from $10.6 million in the prior quarter.
  • The five-year high for Depreciation and Depletion was $14.1 million in Q1 2025, with the low at $8.7 million in Q3 2022.
  • Average Depreciation and Depletion over 5 years is $11.0 million, with a median of $10.8 million recorded in 2023.
  • Year-over-year, Depreciation and Depletion plummeted 41.91% in 2021 and then grew 22.99% in 2023.
  • Tracing BMRN's Depreciation and Depletion over 5 years: stood at $10.4 million in 2021, then dropped by 16.35% to $8.7 million in 2022, then grew by 22.99% to $10.7 million in 2023, then grew by 8.41% to $11.6 million in 2024, then increased by 13.79% to $13.2 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Depreciation and Depletion are $13.2 million (Q4 2025), $10.6 million (Q3 2025), and $10.6 million (Q2 2025).